AAAAAA

   
Results: 1-25 | 26-50 | 51-67
Results: 1-25/67
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry
Authors: Woo, EW Messmann, R Sausville, EA Figg, WD
Citation: Ew. Woo et al., Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry, J CHROMAT B, 759(2), 2001, pp. 247-257
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
Authors: Gilbert, J Baker, SD Bowling, MK Grochow, L Figg, WD Zabelina, Y Donehower, RC Carducci, MA
Citation: J. Gilbert et al., A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies, CLIN CANC R, 7(8), 2001, pp. 2292-2300
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Authors: Gore, SD Weng, LJ Zhai, S Figg, WD Donehower, RC Dover, GJ Grever, M Griffin, CA Grochow, LB Rowinsky, EK Zabalena, Y Hawkins, EK Burks, K Miller, CB
Citation: Sd. Gore et al., Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia, CLIN CANC R, 7(8), 2001, pp. 2330-2339
Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay
Authors: Kruger, EA Figg, WD
Citation: Ea. Kruger et Wd. Figg, Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay, CLIN CANC R, 7(7), 2001, pp. 1867-1872
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
Authors: Figg, WD Dahut, W Duray, P Hamilton, M Tompkins, A Steinberg, SM Jones, E Premkumar, A Linehan, WM Floeter, MK Chen, CC Dixon, S Kohler, DR Kruger, EA Gubish, E Pluda, JM Reed, E
Citation: Wd. Figg et al., A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer, CLIN CANC R, 7(7), 2001, pp. 1888-1893
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solidtumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction
Authors: Kohn, EC Reed, E Sarosy, GA Minasian, L Bauer, KS Bostick-Bruton, F Kulpa, V Fuse, E Tompkins, A Noone, M Goldspiel, B Pluda, J Figg, WD Liotta, LA
Citation: Ec. Kohn et al., A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solidtumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction, CLIN CANC R, 7(6), 2001, pp. 1600-1609
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6 alpha-hydroxypaclitaxel, a major metabolite of paclitaxel
Authors: Kang, MH Figg, WD Ando, Y Blagosklonny, MV Liewehr, D Fojo, T Bates, SE
Citation: Mh. Kang et al., The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6 alpha-hydroxypaclitaxel, a major metabolite of paclitaxel, CLIN CANC R, 7(6), 2001, pp. 1610-1617
Laparoscopic continuous hyperthermic peritoneal perfusion
Authors: Chang, E Alexander, HR Libutti, SK Hurst, R Zhai, SP Figg, WD Bartlett, DL
Citation: E. Chang et al., Laparoscopic continuous hyperthermic peritoneal perfusion, J AM COLL S, 193(2), 2001, pp. 225-229
Resistance to growth inhibitory and apoptotic effects of phorbol ester andUCN-01 in aggressive cancer cell lines
Authors: Blagosklonny, MV Dixon, SC Robey, R Figg, WD
Citation: Mv. Blagosklonny et al., Resistance to growth inhibitory and apoptotic effects of phorbol ester andUCN-01 in aggressive cancer cell lines, INT J ONCOL, 18(4), 2001, pp. 697-704
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressingleukemia cells to cytotoxic chemotherapy
Authors: Blagosklonny, MV Fojo, T Bhalla, KN Kim, JS Trepel, JB Figg, WD Rivera, Y Neckers, LM
Citation: Mv. Blagosklonny et al., The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressingleukemia cells to cytotoxic chemotherapy, LEUKEMIA, 15(10), 2001, pp. 1537-1543
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
Authors: Sausville, EA Arbuck, SG Messmann, R Headlee, D Bauer, KS Lush, RM Murgo, A Figg, WD Lahusen, T Jaken, S Jing, XX Roberge, M Fuse, E Kuwabara, T Senderowicz, AM
Citation: Ea. Sausville et al., Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms, J CL ONCOL, 19(8), 2001, pp. 2319-2333
Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer
Authors: Sunwoo, JB Herscher, LL Kroog, GS Thomas, GR Ondrey, FG Duffey, DC Solomon, BI Boss, C Albert, PS McCullugh, L Rudy, S Muir, C Zhai, S Figg, WD Cook, JA Mitchell, JB Van Waes, C
Citation: Jb. Sunwoo et al., Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer, J CL ONCOL, 19(3), 2001, pp. 800-811
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833
Authors: Chico, I Kang, MH Bergan, R Abraham, J Bakke, S Meadows, B Rutt, A Robey, R Choyke, P Merino, M Goldspiel, B Smith, T Steinberg, S Figg, WD Fojo, T Bates, S
Citation: I. Chico et al., Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833, J CL ONCOL, 19(3), 2001, pp. 832-842
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
Authors: Rudek, MA Figg, WD Dyer, V Dahut, W Turner, ML Steinberg, SM Liewehr, DJ Kohler, DR Pluda, JM Reed, E
Citation: Ma. Rudek et al., Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer, J CL ONCOL, 19(2), 2001, pp. 584-592
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3
Authors: Rudek, MA Horne, M Figg, WD Dahut, W Dyer, V Pluda, JM Reed, E
Citation: Ma. Rudek et al., Reversible sideroblastic anemia associated with the tetracycline analogue COL-3, AM J HEMAT, 67(1), 2001, pp. 51-53
Phenylacetate pharmacokinetics based on iterative two-stage population analysis
Authors: Burstein, AH Reed, E Tompkins, AC Venzon, D Figg, WD
Citation: Ah. Burstein et al., Phenylacetate pharmacokinetics based on iterative two-stage population analysis, PHARMACOTHE, 21(3), 2001, pp. 281-286
Alendronate does not interfere with Tc-99m-methylene diphosphonate bone scanning
Authors: Carrasquillo, JA Whatley, M Dyer, V Figg, WD Dahut, W
Citation: Ja. Carrasquillo et al., Alendronate does not interfere with Tc-99m-methylene diphosphonate bone scanning, J NUCL MED, 42(9), 2001, pp. 1359-1363
Thalidomide neuropathy in patients treated for metastatic prostate cancer
Authors: Molloy, FM Floeter, MK Syed, NA Sandbrink, F Culcea, E Steinberg, SM Dahut, W Pluda, J Kruger, EA Reed, E Figg, WD
Citation: Fm. Molloy et al., Thalidomide neuropathy in patients treated for metastatic prostate cancer, MUSCLE NERV, 24(8), 2001, pp. 1050-1057
Approaches to preclinical screening of antiangiogenic agents
Authors: Kruger, EA Duray, PH Price, DK Pluda, JM Figg, WD
Citation: Ea. Kruger et al., Approaches to preclinical screening of antiangiogenic agents, SEMIN ONCOL, 28(6), 2001, pp. 570-576
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
Authors: Figg, WD Arlen, P Gulley, J Fernandez, P Noone, M Fedenko, K Hamilton, M Parker, C Kruger, EA Pluda, J Dahut, WL
Citation: Wd. Figg et al., A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer, SEMIN ONCOL, 28(4), 2001, pp. 62-66
Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer
Authors: Bartlett, DL Libutti, SK Figg, WD Fraker, DL Alexander, HR
Citation: Dl. Bartlett et al., Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer, SURGERY, 129(2), 2001, pp. 176-187
The control of prostate-specific antigen expression and gene regulation bypharmacological agents
Authors: Dixon, SC Knopf, KB Figg, WD
Citation: Sc. Dixon et al., The control of prostate-specific antigen expression and gene regulation bypharmacological agents, PHARM REV, 53(1), 2001, pp. 73-91
Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specificdrug inactivation?
Authors: Rochat, B Morsman, JM Murray, GI Figg, WD Mcleod, HL
Citation: B. Rochat et al., Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specificdrug inactivation?, J PHARM EXP, 296(2), 2001, pp. 537-541
The androgen receptor gene and its influence on the development and progression of prostate cancer
Authors: Montgomery, JS Price, DK Figg, WD
Citation: Js. Montgomery et al., The androgen receptor gene and its influence on the development and progression of prostate cancer, J PATHOLOGY, 195(2), 2001, pp. 138-146
A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar)
Authors: Bates, S Kang, M Meadows, B Bakke, S Choyke, P Merino, M Goldspiel, B Chico, I Smith, T Chen, C Robey, R Bergan, R Figg, WD Fojo, T
Citation: S. Bates et al., A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar), CANCER, 92(6), 2001, pp. 1577-1590
Risultati: 1-25 | 26-50 | 51-67